Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Key Highlights
- ➤Immix Biopharma (IMMX) prices 11,363,637 shares at $11.00 each
- ➤Gross proceeds expected at $125 million before offering expenses
- ➤Proceeds to fund NXC-201 development, working capital and general corporate purposes
- ➤Offering expected to close on or about September 30, 2026
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.
Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.
Get started
Create a free account to read the full story.